Key Highlights

  • SXTC closed at $2.68 and $0.0698 on 27 July, down about 97.4%, as daily volume rose from roughly 10,000 shares to over 340 million.
  • A $9 million offering of units at $2.00 closed on 24 July; its warrants can settle for up to 63 million shares at zero exercise price.
  • Five reverse splits since 2021 compound to about one share per 2.4 million previously held.
  • The listing risk is acute and rule-based. Nasdaq Rule 5810(c)(3)(A) provides that a company failing the $1.00 minimum bid requirement is ineligible for any compliance period if it has effected a reverse split in the prior year, or cumulative splits of 250-to-1 or more over.

Why China SXT Pharmaceuticals Stock Is in Focus

China SXT Pharmaceuticals, Inc. (NASDAQ:SXTC) is a British Virgin Islands-incorporated maker of traditional Chinese medicine pieces, based in Taizhou, Jiangsu province. Its Class A ordinary shares (not units, warrants or preferred stock) trade on the Nasdaq Capital Market under SXTC. As a foreign private issuer it files Forms 20-F and 6-K, and its fiscal year ends 31 March, so "fiscal 2026" means the year.

It drew attention in late July 2026 for a burst of volume and a near-total price collapse around a capital raise.

The Latest Verified Development

A prospectus supplement covered 4,500,000 units at $2.00, each pairing one Class A ordinary share with one warrant exercisable at $3.20 for a year. Univest Securities was sole placement agent for a 7.0% fee of $630,000. A Form 6-K filed 24 July confirms the offering closed that day for $9,000,000 gross: money documented as received, not merely announced.

The same 6-K discloses a "zero exercise price" alternative permitting up to 63,000,000 Class A shares from those warrants. The supplement recorded 38,218,077 shares outstanding beforehand and a last sale price of $2.02 on 22 July.

What the Volume Surge Actually Shows

Volume is the most verifiable part. Through mid-July, SXTC traded in the thousands of shares daily: 4,195 on 13 July, 9,698 on 16 July, 10,428 on 20 July. It then hit 26.5 million on 22 July, 64.0 million on 23 July, 324.1 million on 24 July and 340.4 million on 27 July, per Investing.com.

That is about 755 million shares in four sessions against roughly 42.7 million outstanding after the July issue, near eighteen times the share count, with the peak session some 32,000 times the 20 July figure. That is not accumulation; it is forced supply meeting a thin book.

What Actually Moved the Share Price

The direction contradicts any "lifeline" reading. SXTC closed at $2.68 on 21 July, $2.02 on 22 July, $0.3326 on 23 July (down 83.5%), $0.0638 on 24 July (down 80.8%) and $0.0698 on 27 July: about 97.4% in four regular sessions.

No reverse split occurred in this window, so the move is not a split artifact. The likeliest mechanical explanation sits in the filings: on 7 July the company registered 157,500,000 shares for resale by Smart Mart Limited under a 3 July agreement priced at 50% of either the closing price at signing or the lowest close over the prior 180 trading days, floored at $0.20. Linking that pipeline to specific sessions is not a company statement.

Recent Financial Performance

For fiscal 2026, the audited 20-F filed reports revenue of $1,138,052, down 34.6% from $1,740,907 in fiscal 2025 and $1,928,497 in fiscal 2024. Gross profit was $248,702. Administrative costs rose to $7,127,450 from $2,758,047, giving an operating loss of $7,122,933 and a net loss of $6,205,085, or $9.13 a share.

Business Model and Principal Assets

Its products are principally Directly-Oral and After-Soaking-Oral medicine pieces, with operations dating to 2005. Fixed assets are minimal: property, plant and equipment of $117,103 and intangibles of $6,328. The fiscal 2025 annual report disclosed one customer at 68.72% of revenue, against two at 45.65% and 16.92% a year before.

A History of Reverse Splits and Issuance

Filings and Nasdaq corporate action records document five reverse splits: 1-for-4, 1-for-20, 1-for-25, 1-for-8 and 1-for-150, compounding to roughly 1-for-2,400,000.

Issuance runs the other way as fast. February's consolidation cut 143,693,892 shares to about 957,960; by 23 July there were 38,218,077, forty times that in under six months. In between: a $9.9 million January placement at $0.15, 2,000,000 shares at $0.38 in April, and a May Regulation S placement of 3,500,000 shares at $1.00 whose warrants were exchangeable for nine times their underlying shares.

Growth Opportunities

The credible upside case rests on cash rather than commerce: repeated raises left far more cash than operations consume, which could fund product expansion or acquisitions. A June 2026 prospectus supplement contemplates up to $100,000,000 of share sales for purposes including "potential acquisitions." No transaction, milestone or contract has been announced.

Balance Sheet and Funding Position

The company held cash of $28,175,865, total assets of $34,754,574, liabilities of $5,047,152 and equity of $29,707,422. Borrowings were roughly $1.0 million, and no going-concern qualification appears in the fiscal 2026 audit information. Auditor Enrome LLP is Singapore-based, PCAOB firm ID 6907 and subject to inspection, relevant to the Holding Foreign Companies Accountable Act the company lists as a delisting risk.

Why the Stock Is Highly Speculative

Market capitalization is roughly $2.2 million on 32.22 million shares per aggregated market data; Investing.com showed $10.72 million on the same count using a stale price. Both predate the July issue, so treat these as approximations observed that period. Free float is not separately disclosed. Five reverse splits plus relentless issuance have compressed legacy holders to a rounding error. Warrants can settle into 63 million shares at zero cost, and 157.5 million further shares are registered for resale under a 50%-discount formula. Cash burn continues against sub-$1.2 million revenue, most of it from one customer, and related-party receivables grew five-fold. The share structure was reorganized into Class A and Class B, and Nasdaq bid-price deficiency letters arrived in November 2022 and October 2024 before compliance was regained in March 2025.

Dilution, Listing and Execution Risks

The listing risk is acute and rule-based. Nasdaq Rule 5810(c)(3)(A) provides that a company failing the $1.00 minimum bid requirement is ineligible for any compliance period if it has effected a reverse split in the prior year, or cumulative splits of 250-to-1 or more over two years. SXTC's 1-for-8 and 1-for-150 splits compound to 1,200-to-1. Read against the filings, a 30-business-day deficiency would bring an immediate Staff Delisting Determination rather than a 180-day cure, and another reverse split would not fix it. That reading is an interpretation, not Nasdaq's.

Competitive and Industry Context

China's traditional medicine pieces sector is fragmented, price-sensitive and governed by PRC manufacturing rules. With annual revenue near $1.1 million and three straight years of decline, SXT is sub-scale against domestic listed peers. Its equity story is driven by financing mechanics, not commercial expansion.

Valuation and Investor Expectations

Conventional multiples do not apply: a price/earnings ratio cannot be computed because the company is loss-making at every level, and enterprise value is distorted because cash of $28.2 million exceeded the whole late-July market capitalization several times over. That gap either signals mispricing or reflects dilution not yet in provider share counts. No analyst coverage or guidance was located, and multiples change continuously.

Conclusion

The verifiable record is narrow and unflattering: shrinking revenue, widening losses, a large cash pile, extreme concentration, and a capital structure built for issuance. The $9 million raise closed and that cash is real. Whether any reaches shareholders per share depends on how many shares exist when it is spent, and on whether the listing survives rules offering no reverse-split escape.

This article is for informational purposes only and does not constitute investment advice or a recommendation to buy, sell, or hold any security. Share prices can rise or fall, and past performance does not guarantee future results. Investors should conduct independent research and consult a licensed financial adviser before making investment decisions.